Valuation: Theraclion

Market Cap 44.6M 51.39M 41.76M 38.2M 72.11M 4.9B 73.06M 489M 192M 2.45B 193M 189M 8.14B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 52.45M 60.44M 49.11M 44.92M 84.81M 5.76B 85.92M 575M 225M 2.88B 227M 222M 9.57B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day-3.55%
1 week+2.70%
Current month+5.17%
1 month-1.89%
3 months+29.25%
1 week 0.54
Extreme 0.542
0.59
1 month 0.54
Extreme 0.542
0.65
Current year 0.44
Extreme 0.436
0.93
1 year 0.44
Extreme 0.436
0.93
3 years 0.44
Extreme 0.436
0.93
5 years 0.44
Extreme 0.436
0.93
10 years 0.44
Extreme 0.436
0.93
Manager TitleAgeSince
Chief Executive Officer - 23/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 31/01/2018
Director/Board Member - 12/02/2019
Director/Board Member - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-3.55%+2.70% - - 51.49M
-0.67%-0.33%+28.05%+4.18% 214B
-1.10%+0.77%+1.29%-22.66% 140B
-0.18%+6.19%-20.94%+21.20% 133B
+4.30%+8.51%-51.52%-1.61% 69.19B
-0.43%+1.94%+12.72%+10.98% 51.28B
-0.36%+5.11%-14.27%-19.86% 50.43B
-1.05%+0.74%+23.41%+10.46% 39.85B
-1.39%+3.66%+41.95%+36.07% 39.27B
+0.03%+8.11%-19.61%+20.79% 32.32B
Average -0.44%+3.77%+0.12%+6.62% 85.43B
Weighted average by Cap. -0.23%+3.04%+2.23%+3.22%

Financials

2024 2025
Net sales 830K 957K 777K 711K 1.34M 91.13M 1.36M 9.09M 3.57M 45.53M 3.59M 3.51M 152M 652K 751K 611K 558K 1.05M 71.57M 1.07M 7.14M 2.8M 35.76M 2.82M 2.76M 119M
Net income -5.76M -6.63M -5.39M -4.93M -9.31M -632M -9.43M -63.07M -24.75M -316M -24.91M -24.37M -1.05B -5.69M -6.56M -5.33M -4.87M -9.2M -625M -9.32M -62.33M -24.46M -312M -24.62M -24.08M -1.04B
Net Debt 3.41M 3.93M 3.19M 2.92M 5.52M 374M 5.59M 37.36M 14.66M 187M 14.76M 14.44M 623M 7.85M 9.05M 7.35M 6.73M 12.7M 862M 12.86M 86.02M 33.76M 431M 33.97M 33.23M 1.43B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change
06/08/26 0.5700 -3.55%
05/08/26 €0.5910 0.00%
04/08/26 €0.5910 +9.04%
03/08/26 €0.5420 0.00%
31/07/26 €0.5420 -2.34%

Annual profits - Rate of surprise